Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $626.00 Price Target at Barclays

Key Points

• Barclays raised its Vertex price target from $617 to $626 and maintained an “overweight” rating, implying 14.53% upside from the share price cited in the report.
• Analyst sentiment is broadly positive: Vertex has a “Moderate Buy” consensus rating and an average price target of $596.44, with several firms recently lifting their targets.
• Vertex’s latest quarter showed revenue of $3.44 billion, above estimates and up 11.8% year over year, while earnings of $4.76 per share fell slightly short of expectations.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price target boosted by analysts at Barclays from $617.00 to $626.00 in a report released on Wednesday, Benzinga reports. The firm presently has an "overweight" rating on the pharmaceutical company's stock. Barclays's target price points to a potential upside of 14.53% from the company's current price.

Other research analysts have also issued research reports about the stock. Wells Fargo & Company increased their target price on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an "overweight" rating in a research report on Tuesday. UBS Group raised their target price on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a "buy" rating in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an "overweight" rating in a research report on Tuesday. Morgan Stanley cut their price target on Vertex Pharmaceuticals from $665.00 to $660.00 and set an "overweight" rating for the company in a research note on Tuesday. Finally, Weiss Ratings raised Vertex Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a research report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $596.44.

Vertex Pharmaceuticals Stock Up 3.0%

Shares of Vertex Pharmaceuticals stock traded up $15.81 on Wednesday, hitting $546.57. The stock had a trading volume of 883,254 shares, compared to its average volume of 1,391,682. Vertex Pharmaceuticals has a twelve month low of $406.67 and a twelve month high of $568.67. The business's 50 day moving average is $522.98 and its two-hundred day moving average is $480.37. The stock has a market cap of $138.72 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 2.65 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 22.40% and a net margin of 30.70%. The business's revenue for the quarter was up 11.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.80 earnings per share. As a group, equities analysts predict that Vertex Pharmaceuticals will post 16.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Gryphon Financial Partners LLC grew its stake in shares of Vertex Pharmaceuticals by 1.8% in the third quarter. Gryphon Financial Partners LLC now owns 1,878 shares of the pharmaceutical company's stock worth $982,000 after purchasing an additional 34 shares during the last quarter. Kestra Investment Management LLC raised its position in Vertex Pharmaceuticals by 10.3% during the 3rd quarter. Kestra Investment Management LLC now owns 760 shares of the pharmaceutical company's stock valued at $398,000 after purchasing an additional 71 shares during the last quarter. AlphaCore Capital LLC raised its position in Vertex Pharmaceuticals by 10.5% during the 3rd quarter. AlphaCore Capital LLC now owns 3,599 shares of the pharmaceutical company's stock valued at $1,881,000 after purchasing an additional 341 shares during the last quarter. Leuthold Group LLC lifted its holdings in Vertex Pharmaceuticals by 9.4% in the 3rd quarter. Leuthold Group LLC now owns 17,113 shares of the pharmaceutical company's stock worth $8,947,000 after buying an additional 1,473 shares during the period. Finally, Joseph Group Capital Management lifted its holdings in Vertex Pharmaceuticals by 3.1% in the 3rd quarter. Joseph Group Capital Management now owns 11,085 shares of the pharmaceutical company's stock worth $5,795,000 after buying an additional 329 shares during the period. 90.96% of the stock is owned by institutional investors.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 12% year over year to $3.44 billion, topping estimates, as cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributed to growth. Vertex raised its 2026 revenue outlook to $13.15 billion–$13.25 billion. Article: Vertex Pharmaceuticals Q3 Earnings Call Highlights
• Positive Sentiment: Povetacicept, a potential treatment for IgA nephropathy, is approaching an FDA decision expected November 30. Management expressed confidence in the program and launch preparations, making it an important potential growth driver beyond cystic fibrosis. Article: Vertex, ahead of FDA decision, calms fears surrounding kidney drug
• Positive Sentiment: Analyst sentiment was broadly constructive, with several firms raising price targets after the report; RBC also pointed to possible further appreciation if povetacicept is approved and launched. Article: Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept
• Negative Sentiment: Adjusted earnings of $4.76 per share missed analyst expectations, despite the revenue beat. Higher launch-related spending and costs associated with the Crinetics acquisition pressured profitability. Article: VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
• Negative Sentiment: Reports also highlighted lighter-than-hoped-for sales of the pain drug JOURNAVX, raising questions about the pace of growth from newer products. That concern, alongside the earnings shortfall, helps explain the mixed market reaction to results. Article: Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.